639P 223Ra in asymptomatic patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed to first-line abiraterone acetate or enzalutamide

Autor:	Cristina Suarez, C. Garcías de España, B. Mellado Gonzalez, S. Vazquez Estevez, P. Borrega García, Teresa Alonso, A. González del Alba, Joan Carles, Rosa Collado, M.J. Mendez Vidal, Eduard Gallardo, J. Garde, R. Morales Barrera, Andrea Malfettone, Josep M. Piulats, T. Bonfill, Pilar Paredes, Òscar Reig
Rok vydání:	2020
Předmět:	Oncology medicine.medical_specialty business.industry First line Abiraterone acetate Hematology Castration resistant medicine.disease Asymptomatic chemistry.chemical_compound Prostate cancer chemistry Internal medicine Medicine Enzalutamide medicine.symptom business
Zdroj:	Annals of Oncology. 31:S525-S526
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2020.08.898
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a1d72f95197352db856e29842c1cd484 https://doi.org/10.1016/j.annonc.2020.08.898 Zobrazit plný text záznamu